PORTFOLIO NEWS Tenaya Therapeutics Closes $92 Million Series B Financing October 3, 2019 Read More » NGM Bio Announces Multiple Aldafermin (NGM282) Poster Presentations at Upcoming AASLD’s The Liver Meeting October 3, 2019 Read More » Constellation Pharmaceuticals Announces $65 Million Private Placement with New and Existing Investors October 1, 2019 Read More » Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise September 24, 2019 Read More » REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor September 17, 2019 Read More » Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor September 4, 2019 Read More » Kallyope Inc. Appoints Juha Lauren as Chief Business Officer September 4, 2019 Read More » Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor September 4, 2019 Read More » Accent Therapeutics Appoints Shakti Narayan as Chief Executive Officer September 3, 2019 Read More » Gritstone Oncology Announces First Patient Dosed with SLATE, its “Off-The-Shelf” Neoantigen Immunotherapy August 14, 2019 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
NGM Bio Announces Multiple Aldafermin (NGM282) Poster Presentations at Upcoming AASLD’s The Liver Meeting October 3, 2019 Read More »
Constellation Pharmaceuticals Announces $65 Million Private Placement with New and Existing Investors October 1, 2019 Read More »
Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise September 24, 2019 Read More »
REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor September 17, 2019 Read More »
Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor September 4, 2019 Read More »
Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor September 4, 2019 Read More »
Gritstone Oncology Announces First Patient Dosed with SLATE, its “Off-The-Shelf” Neoantigen Immunotherapy August 14, 2019 Read More »
